DelveInsight’s, “AL Amyloidosis Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in AL Amyloidosis pipeline landscape. It covers the AL Amyloidosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the AL Amyloidosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the AL Amyloidosis Pipeline. Dive into DelveInsight’s comprehensive report today! @ AL Amyloidosis Pipeline Outlook

Key Takeaways from the AL Amyloidosis Pipeline Report

• In February 2025:- Janssen Research & Development LLC:- The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.
• In February 2025:- AbbVie:- Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by clonal bone marrow plasma cells. This is a study to determine adverse events and change in disease activity in adult participants with AL amyloidosis treated with ABBV-383.
• DelveInsight’s AL Amyloidosis pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for AL Amyloidosis treatment.
• The leading AL Amyloidosis Companies such as Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, ZENTALIS PHARMACEUTICALS, Sorrento Therapeutics, Inc., and others.
• Promising AL Amyloidosis Therapies such as Belantamab mafodotin, CAEL-101, Daratumumab SC, Pomalidomide, Dexamethasone, and others.

Stay ahead with the most recent pipeline outlook for AL Amyloidosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ AL Amyloidosis Treatment Drugs

AL Amyloidosis Emerging Drugs

• CAEL-101: Caelum Biosciences

CAEL-101 is a fibril-reactive monoclonal antibody (mAb) that is currently in Phase III clinical development for the treatment of patients with amyloid light chain (“AL”) amyloidosis. The Cardiac Amyloid Reaching for Extended Survival (CARES) clinical program includes two parallel Phase III studies – one in patients with Mayo stage IIIa disease and one in patients with Mayo stage IIIb disease – and will collectively enroll approximately 370 patients globally. The primary objective of the clinical program is to assess overall survival. CAEL-101 has received Orphan Drug Designation from both the US Food and Drug Administration and European Medicine Agency as a therapy for patients with AL amyloidosis.

• NXC-201: Nexcella, Inc.

NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis. The design consists of a structurally differentiated CAR-T, with the proprietary BCMA-targeting CAR, which has demonstrated reduced toxicity in NEXICART-1, supporting investigating NXC-201 as an outpatient therapy. It is currently in Phase I NEXICART-1 study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy for the treatment of patients with relapsed or refractory multiple myeloma and light chain amyloidosis (AL).

The AL Amyloidosis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of AL Amyloidosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for AL Amyloidosis Treatment.
• AL Amyloidosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• AL Amyloidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the AL Amyloidosis market.

Explore groundbreaking therapies and clinical trials in the AL Amyloidosis Pipeline. Access DelveInsight’s detailed report now! @ New AL Amyloidosis Drugs

AL Amyloidosis Companies

Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, ZENTALIS PHARMACEUTICALS, Sorrento Therapeutics, Inc., and others.

AL Amyloidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

AL Amyloidosis Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Unveil the future of AL Amyloidosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ AL Amyloidosis Market Drivers and Barriers

Scope of the AL Amyloidosis Pipeline Report

• Coverage- Global
• AL Amyloidosis Companies- Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, ZENTALIS PHARMACEUTICALS, Sorrento Therapeutics, Inc., and others.
• AL Amyloidosis Therapies- Belantamab mafodotin, CAEL-101, Daratumumab SC, Pomalidomide, Dexamethasone, and others.
• AL Amyloidosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• AL Amyloidosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on AL Amyloidosis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ AL Amyloidosis Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. AL Amyloidosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. AL Amyloidosis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. CAEL-101: Caelum Biosciences
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NXC-201: Nexcella, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. LambdaMab 10B3 & 7F11: HaemaLogiX Ltd.
18. Drug profiles in the detailed report…..
19. Inactive Products
20. AL Amyloidosis Key Companies
21. AL Amyloidosis Key Products
22. AL Amyloidosis- Unmet Needs
23. AL Amyloidosis- Market Drivers and Barriers
24. AL Amyloidosis- Future Perspectives and Conclusion
25. AL Amyloidosis Analyst Views
26. AL Amyloidosis Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market